These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 6045024)

  • 41. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis.
    Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2004 Apr; 23(4):414-5. PubMed ID: 15081096
    [No Abstract]   [Full Text] [Related]  

  • 42. [Morphologic and biochemical changes in Mycobacterium tuberculosis during chemotherapy].
    Khomenko AG; Fadeeva NI; Golyshevskaia VI
    Probl Tuberk; 1983 Jul; (7):48-54. PubMed ID: 6415652
    [No Abstract]   [Full Text] [Related]  

  • 43. [The virulence of resistant strains of Mycobacterium tuberculosis for guinea pigs and experimental therapeutic effects of antitubercular agents on the animals infected by the resistant strains. I. The virulence of the resistant strains of Mycobacterium tuberculosis].
    Wang XG
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1982 Aug; 5(4):204-6. PubMed ID: 6816557
    [No Abstract]   [Full Text] [Related]  

  • 44. [Morphazinamide in the treatment of urogenital tuberculosis in a sanatorium. 1st trials].
    Kalachnikoff P; Laugie H; Lengrand J
    J Urol Nephrol (Paris); 1966; 72(10):756-61. PubMed ID: 5972482
    [No Abstract]   [Full Text] [Related]  

  • 45. [TREATMENT OF PULMONARY TUBERCULOSIS WITH MORPHAZINAMIDE (PIAZOLINA)].
    STEIGER J
    Ther Umsch; 1964 Oct; 21():396-8. PubMed ID: 14323356
    [No Abstract]   [Full Text] [Related]  

  • 46. [Dynamics of bacterial populations in experimental destructive pulmonary tuberculosis under treatment].
    Golişevskaia V
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1981; 30(2):111-4. PubMed ID: 6264575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Recent possibilities of an antimycotic therapy].
    Wohlrab W; Wozniak D; Schwabe K; Tschierch B; Tanneberger S; Zaumseil RP; Taube KM
    Dermatol Monatsschr; 1982 Jun; 168(6):418-9. PubMed ID: 7117640
    [No Abstract]   [Full Text] [Related]  

  • 48. Preclinical testing of new drugs for tuberculosis: current challenges.
    Lenaerts AJ; Degroote MA; Orme IM
    Trends Microbiol; 2008 Feb; 16(2):48-54. PubMed ID: 18182291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Experimental study of chemoprophylaxis of tuberculosis].
    Klebanov MA; Rotov VI; Bogaevskiĭ AT; Andriushchenko VV; Govorov AM; Kassich IuIa; Shmaliĭ KV; Sokalo SV
    Probl Tuberk; 1965; 43(1):51-8. PubMed ID: 5832067
    [No Abstract]   [Full Text] [Related]  

  • 50. [Toxicity of 4-chloroanilid of 5-chlorosalicylic acid (arylid) for various species of laboratory animals].
    Krysicka-Doczkal H; Szafranowa H
    Gruzlica; 1969 Jun; 37(6):511-6. PubMed ID: 5350916
    [No Abstract]   [Full Text] [Related]  

  • 51. Anti tubercular activity of garlic oil.
    Jain RC
    Indian J Pathol Microbiol; 1998 Jan; 41(1):131. PubMed ID: 9581089
    [No Abstract]   [Full Text] [Related]  

  • 52. [EXPERIMENTAL TESTS "IN VIVO" ON THE ANTIMYCOBACTERIAL ACTION OF MORPHAZINAMIDE].
    BLASI A
    G Ital Chemioter; 1963; 10():51-5. PubMed ID: 14085318
    [No Abstract]   [Full Text] [Related]  

  • 53. [Macrophage migration inhibition reaction as an index of the effectiveness of the intermittent and continuous chemotherapy of tuberculosis].
    Sibirnaia RI
    Probl Tuberk; 1980 Sep; (9):69-71. PubMed ID: 7422664
    [No Abstract]   [Full Text] [Related]  

  • 54. [The virulence of drug-resistant Mycobacterium tuberculosis in animals and the therapeutic effect and biochemical changes of the drugs].
    Zhao T
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1984 Apr; 7(2):76-7. PubMed ID: 6435977
    [No Abstract]   [Full Text] [Related]  

  • 55. [THE EFFECT OF CALCIUM PANTOTHENATE ON THE EFFECTIVENESS OF ANTIBACTERIAL THERAPY OF EXPERIMENTAL TUBERCULOSIS].
    SHEFER LB
    Probl Tuberk; 1963; 41():64-9. PubMed ID: 14069173
    [No Abstract]   [Full Text] [Related]  

  • 56. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
    Pandey R; Khuller GK
    Tuberculosis (Edinb); 2005 Jul; 85(4):227-34. PubMed ID: 15922668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bacteriologic basis of short-course chemotherapy for tuberculosis.
    Grosset J
    Clin Chest Med; 1980 May; 1(2):231-41. PubMed ID: 6794976
    [No Abstract]   [Full Text] [Related]  

  • 58. [Clinical and experimental data on changes of blood transaminases level during antitubercular antibiotherapy].
    Despierres G; Viallier J; Cayre RM
    Lyon Med; 1967 Dec; 218(51):1629-40. PubMed ID: 5622039
    [No Abstract]   [Full Text] [Related]  

  • 59. [The place of isoxyl in relay antibiotic therapy of tuberculosis].
    Guillermand J; Favier G; Vaccon G; Faure G
    Rev Tuberc Pneumol (Paris); 1966; 30(2):237-54. PubMed ID: 5950423
    [No Abstract]   [Full Text] [Related]  

  • 60. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
    Sharma A; Sharma S; Khuller GK
    J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.